Reviewer’s report

Title: Persistence on prostaglandin ocular hypotensive therapy: an assessment using medication possession and days covered on therapy

Version: 2 Date: 5 October 2009

Reviewer: John Garnett Walt

Reviewer's report:

All but one of my original criticisms have been answered. I would still like at least one reference on how what they found compares to chronic treatments outside of glaucoma, such as persistence with the class of hypertension and high cholesterol treatment Pfizer makes. As Pfizer employees they should have access to this Pfizer data.

Level of interest: An article whose findings are important to those with closely related research interests

Quality of written English: Acceptable

Statistical review: Yes, but I do not feel adequately qualified to assess the statistics.

Declaration of competing interests:

I am an employee of Allergan.